The U.S. FDA is poised to approve multiple RSV vaccines this year.

The race to an RSV vaccine could soon be over, decades after the first attempt The FDA is poised to approve multiple RSV vaccines this year. The leading candidates are for older adults, but shots to protect infants are in the pipeline. NBC News

Roughly six decades after the first attempt to develop a vaccine for respiratory syncytial virus, the Food and Drug Administration is poised to approve several shots by next winter.

No RSV vaccine has ever been approved in the U.S. The FDA is reviewing two applications — a vaccine from Pfizer and another from GlaxoSmithKline, both of which are for people ages 60 and up.

...